Feedback / Questions
NKT3447 - NiKang Therap
https://www.businesswire.com/news/home/20240415891824/en/NiKang-Therapeutics-Doses-First-Patient-in-a-Phase-11b-Study-of-NKT3447-an-Oral-Selective-Inhibitor-of-CDK2-Which-Reduces-Cyclin-E-Expression
Apr 15, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next